BOTHELL, Wash., April 6 /PRNewswire-FirstCall/ -- Helix BioMedix, Inc.
(OTC: HXBM.OB), a developer of bioactive peptides, today announced several
changes to its Board of Directors. George A. Murray will be retiring from the
Board and will not stand for reelection at the Company's annual meeting of
stockholders scheduled to be held on May 18, 2006. In addition, effective
March 31, 2006 Weston Anson has been appointed to the company's Board of
Directors as a Class III Director and David O'Connor has been appointed as a
Class II Director.
Mr. Anson, age 63, is the Chairman of CONSOR(R), an intellectual asset
consulting firm specializing in trademark, patent and copyright licensing,
valuations and expert testimony. He served for six years as Vice President of
the Licensing Industry Merchandisers' Association and is a lifetime member of
the Board of Advisors. He is also the immediate past Co-Chair of the ABA
Trademark, Licensing Sub-committee and is the newly appointed Co-Chair of the
Asset Sales Committee for the American Bankruptcy Institute. An active member
of the Licensing Executives Society (LES), he is past Chairman of the
Valuation Committee, the Internet Licensing E-Commerce Committee and the
Trademark Licensing Committee. He is currently on the International Board of
LES. Mr. Anson received his B.S. from Northwestern University and holds an
M.B.A. (honors) from Harvard University.
Mr. O'Connor, age 70, is a consultant with Westfield Consultants Group, an
independent business consulting firm. Prior to joining Westfield in 1998, he
was the President and a member of the Board of Directors of Merle Norman
Cosmetics International. Prior to 1992 he held executive positions with
InterCare Medical Group & Emergency Department Physicians Medical Group,
Visage Beaute Cosmetics and Merle Norman Cosmetics, Inc. In addition, Mr.
O'Connor served as the Chairman of the Board of Directors of the Robert F.
Kennedy Medical Center and was President and a member of the Board of
Directors of the Beauty Industry West Trade Association. Mr. O'Connor holds a
B.S. from the University of Oregon and an M.H.A. from the University of
Southern California.
R. Stephen Beatty, President and Chief Executive Officer of Helix
BioMedix, commented, "On behalf of the Board of Directors and the employees of
Helix BioMedix, I would like to thank George Murray for his valuable counsel
and contributions to the company over the last four years. We wish George all
the best in his future endeavors."
"We are also pleased to announce that Weston Anson and David O'Connor have
agreed to join the Helix BioMedix Board," added Mr. Beatty. "Weston's
consumer goods marketing background and his expertise developing effective
licensing strategies are expected to make him a valuable addition to the
Board. We also look forward to benefiting from David's beauty industry
knowledge and contacts. We are fortunate to be able to attract such
accomplished executives and look forward to their contributions as we move
ahead with the development and commercialization of our proprietary peptides."
With the two additions to the Board and after the retirement of Mr. Murray
in May, the number of directors will increase from eight to nine.
About Helix BioMedix
Helix BioMedix, Inc. is a biopharmaceutical company that has a portfolio
of issued patents that covers six distinct classes of peptides, including over
100,000 unique peptide sequences. The company's mission is to become the
industry leader in developing and commercializing small proteins known as
bioactive peptides. The antimicrobial and wound healing properties of these
peptides qualify them for inclusion in a wide range of both pharmaceutical and
consumer products. The company is currently focused on the development of
selected peptides as topical anti-infectives and in wound healing
applications. Non-pharmaceutical applications being pursued by Helix BioMedix
include adjuvants for cosmetics/cosmeceuticals, personal care, plant health,
animal health and wide-spectrum biocides. More information about the company
and its proprietary peptides can be found on the company's website at
http://www.helixbiomedix.com.
Important Notice
This press release contains forward-looking statements (statements which
are not historical facts) within the meaning of the Private Securities
Litigation Reform Act of 1995. These forward-looking statements include
statements regarding activities, events or developments that the company
expects, believes or anticipates may occur in the future, including statements
related to our potential growth, product development and commercialization and
revenue. A number of factors could cause actual results to differ from those
indicated in the forward-looking statements, including the company's ability
to successfully raise additional capital, enter into revenue generating
license agreements, continue its research and development efforts, including
pre-clinical and clinical studies, and general economic conditions. Additional
assumptions, risks and uncertainties are described in detail in our reports
and other filings with the Securities and Exchange Commission. Such filings
are available on our website or at http://www.sec.gov. Readers are cautioned that
such forward-looking statements are not guarantees of future performance and
that actual results or developments may differ materially from those set forth
in the forward-looking statements. The company undertakes no obligation to
publicly update or revise forward-looking statements to reflect subsequent
events or circumstances.
Contact: Investor Relations:
Helix BioMedix, Inc. Cameron Associates
David H. Kirske, 425-402-8400 Alison Ziegler, 212-554-5469
dkirske@helixbiomedix.com alison@cameronassoc.com
SOURCE Helix BioMedix, Inc.
 back to top
Related links:
http://www.helixbiomedix.com
CONTACT:
David H. Kirske of Helix BioMedix, Inc.,
+1-425-402-8400, or dkirske@helixbiomedix.com; or investors,
Alison Ziegler of Cameron Associates, +1-212-554-5469, or
alison@cameronassoc.com, for Helix BioMedix, Inc.
|
